Phase 3 trial clearance is based on the Phase 1/2 results demonstrating safety and efficacy of the 3x10¹³ vg/kg dose of microdystrophin, which is lower than doses used in other gene therapies for Duchenne muscular dystrophy (DMD).

The double blind trial will initiated in the UK and France beginning in August and September, and will enroll 64 boys aged 6 to 10 with DMD who have retained their walking ability.

The AADOCR is now accepting applications for Cohort 6 of the Mind the Future Program, thanks to the generous support of CareQuest Institute for Oral Health. 

People in 15 regions across the U.S. will soon benefit from the American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative™, designed to improve treatment of the interconnected conditions that lead to heart disease and stroke.

The findings significantly advance our biological understanding of the condition, shedding light on potential avenues for new treatments.

More than 11,000 additional women opted for the most effective form of birth control—long-acting reversible contraception (LARC)—within just 15 months of B.C. making prescription contraception free. The study tracked nearly 860,000 women aged 15–49 and found that cost had been a major barrier to accessing the most effective methods like intrauterine devices (IUDs) and implants, which can cost up to $450 out of pocket. LARC methods are 10 times more effective than the birth control pill or condoms.

A new study suggests the marbling of fat inside our own muscles points to health trouble.